CG
RPRX icon

Cutler Group’s Royalty Pharma RPRX Stock Holding History

Cutler Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-700
Closed -$1K – 5565
2022
Q1 		$1K Buy
+700
New +$27.5K ﹤0.01% 5057
2021
Q3 		– Sell
-13,800
Closed -$57K – 6262
2021
Q2 		$57K Sell
13,800
-200
-1% -$8.51K ﹤0.01% 2386
2021
Q1 		$70K Buy
+14,000
New +$664K ﹤0.01% 2062

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Cutler Group's RPRX Position: Q4 2021 in Review

Cutler Group sold out of Royalty Pharma (RPRX) in Q4 2021, closing a stake of 440 shares — an estimated $17.1K sold.

Cutler Group first reported a position in RPRX in Q3 2020 and held it in 4 quarters. The position peaked at $450K in Q2 2021. 266 funds tracked by Wall St. Rank hold RPRX as of Q4 2021.

  • Cutler Group reported no remaining Royalty Pharma position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 440 Royalty Pharma shares in Q4 2021, an estimated $17.1K.
  • Cutler Group first reported a position in Royalty Pharma in Q3 2020 and held it in 4 quarters.
  • Cutler Group's Royalty Pharma position peaked at $450K in Q2 2021.
  • 266 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.